BBIXF:OTC-Bonus BioGroup Ltd (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.03

Change

-0.01 (-25.00)%

Market Cap

USD 0.05B

Volume

2.00K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
UCBJY UCB SA ADR

-2.01 (-2.14%)

USD 34.52B
UCBJF UCB SA

N/A

USD 33.97B
ARGNF argenx SE

N/A

USD 32.04B
GNMSF Genmab A/S

-2.20 (-0.93%)

USD 16.79B
ZLDPF Zealand Pharma A/S

-7.00 (-5.30%)

USD 9.62B
IVBIY IVBIY

N/A

USD 8.92B
SBMFF Sino Biopharmaceutical Limited

+0.04 (+9.81%)

USD 7.86B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 7.85B
WXIBF WuXi Biologics

N/A

USD 7.06B
WXXWY WuXi Biologics (Cayman) Inc

+0.16 (+4.65%)

USD 7.06B

ETFs Containing BBIXF

QCLN:F First Trust Nasdaq Clean .. 9.08 % 0.00 %

N/A

USD 0.01B
MIDF 1.54 % 0.00 %

N/A

N/A
IXN iShares Global Tech ETF 0.00 % 0.46 %

+1.34 (+0.00%)

N/A
HAIL SPDR S&P Kensho Smart Mob.. 0.00 % 0.46 %

+0.65 (+0.00%)

USD 0.04B
XSD SPDR® S&P Semiconductor .. 0.00 % 0.35 %

+10.55 (+0.00%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 50.00% 78% C+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.00% 78% C+ 87% B+
Trailing 12 Months  
Capital Gain 7,400.00% 100% F 100% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7,400.00% 100% F 100% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 564.10% 89% A- 94% A
Dividend Return 564.10% 89% A- 94% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 2,789.98% 10% F 6% D-
Risk Adjusted Return 20.22% 73% C 54% F
Market Capitalization 0.05B 68% D+ 51% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector